Imugene valuation points to 129% upside as broker backs azer-cel strategy [Yahoo! Finance]
Allogene Therapeutics, Inc. (ALLO)
Last allogene therapeutics, inc. earnings: 2/27 04:30 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
to a new initiation report from RaaS Research , which has assigned the company a risk-adjusted valuation of $0.24 per share — representing 129% upside to the current share price of $0.105. The broker believes the market is yet to fully appreciate Imugene's strategic transformation into a streamlined CAR-T-focused biotech centred on its lead asset azer-cel , an “off-the-shelf” allogeneic CAR-T therapy targeting blood cancers. RaaS said Imugene had undergone a major pivot away from its previously broad and capital-intensive oncology pipeline, with management now concentrating resources on advancing azer-cel through late-stage development and toward commercialisation. The report highlighted what it described as “compelling” Phase 1b efficacy data to date, including an 82% overall response rate in relapsed or refractory diffuse large B-cell lymphoma patients who had failed prior autologous CAR-T therapy, alongside strong results in niche CAR-T naïve lymphoma indications. Broker se
Show less
Read more
Impact Snapshot
Event Time:
ALLO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALLO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALLO alerts
High impacting Allogene Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALLO
News
- Why Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
- Allogene Therapeutics, Inc. (ALLO) A Top Penny Stock to Buy on Robust CAR T-Cell Portfolio [Yahoo! Finance]Yahoo! Finance
- Allogene Therapeutics Announces Planned CEO Succession [Yahoo! Finance]Yahoo! Finance
- Allogene Therapeutics Announces Planned CEO SuccessionGlobeNewswire
- Allogene Therapeutics Announces Participation in Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
ALLO
Earnings
- 5/13/26 - Beat
ALLO
Sec Filings
- 5/28/26 - Form DEFA14A
- 5/28/26 - Form 8-K
- 5/21/26 - Form DEFA14A
- ALLO's page on the SEC website